Development of an immunotoxicology program within the pharmaceutical industry is described. With few guidelines in this area and a multitude of factors to consider, a basic screen for evaluating immune competence in species routinely used in toxicologic studies has been proposed. The future of immunotoxicology depends upon the ability of the selected immune function tests to be predictive of human risk.
The use of immunologic methods over the past several decades has been important in the development of anti-inflammatory drugs. However, the application of immunology within a toxicology environment has only occurred relatively recently. February 1982 on lymphoid organs found in routine toxicity studies; (2) to obtain more insight into the mode of action (i.e., which cell type is the target and which phase of the immune response is impaired).
At first, this may seem to be a reasonable attempt to acknowledge the importance of immunologic testing, but I call to your attention one particular paragraph in these proposed guidelines:
At the termination of a toxicity study, thymus, spleen, and lymph nodes should be weighed and examined microscopically. From these data and measurements of serum immunoglobulin fractions and counts of circulating lymphocytes, the conclusion should be reached whether the substance has an effect on the lymphoid system and whether or not specific function tests have to be performed.
The intent, then, is for immune function tests to be done only after histopathologic and hematologic studies have been performed. There are some important pitfalls to this approach. The first is that histopathologic changes are not a sensitive indicator of drug-induced immunologic toxicity. Generally, histomorphologic changes associated with compromised immune function are seen only at fairly high dosage levels. In addition, the inability to differentiate morphologically between T-cells and B-cells is well known. and accepting a multifaceted approach to delineate the mechanism of drug action (not 
Originally, three fundamental immunologic function areas were designated. The primary objectives were to select tests that could be done in rats, dogs, and monkeys and would interface with the standard operating procedures of our laboratory, such as the collection of blood samples at the same time as routine bleedings for hematologic and serum biochemical studies.
Serum Immunoglobulin Levels
The quantitation of serum immunoglobulin levels, specifically IgG, IgM, and IgA, was chosen as a crude reflection of B-cell activity. Since we usually analyze a relatively large volume of samples in a day, it was apparent that many of the currently available techniques to quantitate specific serum proteins (i.e., radial immunodiffusion, radioimmunoassay, and electroimmunodiffusion) were unsuitable because of lack of automation. Another initial requisite, commercially available reagents, also was not feasible at that time; reagents were available to quantitate human serum immunoglobulins, but not for rats, dogs, and monkeys. We chose to produce monospecific, high avidity antibodies from goats directed against IgG, IgM and IgA from all three species and to use the nephelometric technology developed by Ritchie (5 (6) .
From information available in the murine system we developed a blastogenic assay in the rat. In order to interface with our current standard 55 operating procedures, we modified the whole blood assay described previously by Han and Pauly (7) (see Fig. 1 
Skin Sensitization
New developments in the methodology used to evaluate drug-induced hypersensitivity, or skin sensitization, has made it possible to improve the credibility of certain obligatory tests. The Landsteiner-Draize guinea pig skin test has long been the method of choice for doing skin sensitization. However, the development of the skin maximization test (9) has greatly improved the predictability of the guinea pig model while eliminating false negatives. 
Development of Specific Immune Modulators
While the search for new and better anti-inflammatory compounds is an active program of many institutions, the toxicological examination of these new product candidates, inclusive of immune function testing, offers a broader basis for determining the potential of that particular drug.
New Product Development
The toxicologic testing of compounds that are not specifically designed as immune modulators may, in remote instances, demonstrate immunologic enhancement or impairment. Such information could then be referred back to medicinal chemists and pharmacologists for further development.
Basic Research
To aid in the development of more rapid and reliable assays as well as new immune models, which are critical to understanding the effects of chemicals on the immune response, some effort should be made in an immunotoxicology program to conduct basic research.
Conclusion
The field of immunotoxicology is in the early stages of rapid development. Although the immune response is quite complex, involving a sophisticated array of cellular and molecular interactions, there is increasing evidence that chronic, subclinical exposure to a variety of chemicals does in fact lead to an adverse modification of immune function, manifested most ostensibly by reduced host resistance to infectious agents, such as viruses and bacteria (10) . In many respects, the state-of-the-art is much like mutagenesis was five to ten years ago. Yet we must realize that the progress of immunotoxicology will depend upon the continued, close interaction among persons in academia, industry, as well as governmental institutions. With the approach evolving at MSDRL, it now seems possible to move ahead in this area. Ultimately, a basic screen for Environmental Health Perspectives immune competence needs to be validated using compounds with known immunosuppressive effects as part of a subacute study. 
